Can SLNO's upcoming earnings report revive investor confidence?

**Soleno Therapeutics' (SLNO) upcoming earnings report is unlikely to revive investor confidence** based on the current analyst estimates and recent news. Here's why: 1. **Expected Negative Earnings**: The estimated EPS for SLNO in Fiscal 2025Q1 is -$1.08, which indicates a continued loss for the company. This is a stark contrast from the previous quarter's EPS of -$0.56, which suggests a deteriorating financial situation. 2. **Revenue Expectations**: The estimated revenue for the same quarter is $1 million. This is a modest figure, especially when compared to the company's historical performance and the potential market size for its drug, Vykat XR. The lack of significant revenue growth could further erode investor confidence. 3. **Recent Analyst Ratings**: While there have been some positive analyst ratings, such as HC Wainwright's "Buy" rating and a price target of $70, the recent earnings estimates and the fact that SLNO is not expected to be profitable until FY2025 may lead to caution among investors. 4. **Market Response to FDA Approval**: The FDA approval of Vykat XR was a positive development, but it has not been enough to significantly boost investor confidence. The market may be awaiting more substantial proof of the drug's commercial success before fully embracing SLNO's stock. 5. **Insider Activity**: There have been some insider sales, which could be interpreted as a lack of confidence in the company's short-term prospects. Insider ownership levels may also be influencing investor perceptions. 6. **Options Trading Activity**: The unusual increase in options trading volume, with a 1,271% surge in put options, suggests that investors are hedging their bets or anticipating potential downside risks. This could indicate a lack of confidence in SLNO's immediate future. In conclusion, while SLNO has potential with its FDA-approved drug, Vykat XR, the upcoming earnings report is not likely to instill confidence in investors due to the expected negative earnings and lack of substantial revenue growth. The market will be watching closely for signs of improvement, but at this juncture, the odds are against a revival of investor confidence based on the current projections and recent news.